NCT03660826 · OUTCOME

Markers of Angiogenesis in Serial Plasma Samples

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · Source last updated 2026-08-28

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 5 years

What was measured

Will assess if markers of angiogenesis in serial plasma samples are associated with response to cediranib alone or in combination with olaparib.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Will assess if markers of angiogenesis in serial plasma samples are associated with response to cediranib alone or in combination with olaparib.
reporting Status: NOT_POSTED
time Frame: Up to 5 years
title: Markers of Angiogenesis in Serial Plasma Samples
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice